AI

FDA Clears Uptunity AI for Brain Aneurysm Detection on CT Scans

Bracco and Avicenna.AI's software identifies saccular aneurysms over 3mm and tracks changes in follow-up imaging.

Omega Editorial · November 16, 2026 · 2 min read

Key takeaways

  • The FDA has cleared Uptunity AI software to help radiologists detect brain aneurysms on CT angiography scans.
  • The tool identifies saccular aneurysms greater than 3mm and provides location and size information for clinical assessment.
  • Follow-up features enable quantitative measurements and exam-to-exam comparisons to track aneurysm changes over time.
  • Approximately 1 in 50 U.S. adults have an unruptured brain aneurysm, often asymptomatic and difficult to detect.
  • Bracco and Avicenna.AI are preparing for commercial launch in the U.S. following FDA clearance.

FDA Approves New AI Tool for Aneurysm Detection

The Food and Drug Administration has granted clearance to Uptunity, an artificial intelligence software designed to help radiologists identify brain aneurysms on CT angiography scans. The tool was developed through a partnership between contrast-agent manufacturer Bracco and medical AI company Avicenna.AI, who announced the clearance Friday.

The software addresses a significant clinical challenge: approximately 1 in 50 U.S. adults have an unruptured brain aneurysm, a condition that frequently produces no symptoms and can be difficult to spot on imaging studies.

How the Technology Works

Uptunity operates within radiologists' existing reading environments to flag suspected saccular brain aneurysms larger than 3 millimeters on head CT angiography images. The system provides information about the presence, location, and size of detected aneurysms to support clinical assessment and characterization.

For patients with known aneurysms, the software includes follow-up capabilities that deliver quantitative measurements and enable comparison between successive exams. This functionality helps physicians track whether aneurysms are changing over time, a critical factor in treatment decisions.

"A small incidental aneurysm on a head CTA can easily be overlooked when the work list keeps growing," said Cosimo DePinto, executive vice president of marketing and commercial operations for Bracco Americas. "Uptunity Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan."

Why It Matters

Brain aneurysm detection represents a high-stakes diagnostic challenge where false negatives can have severe consequences. As radiology departments face growing imaging volumes and workload pressures, AI tools that flag potential findings without disrupting workflow could reduce missed diagnoses. The software's ability to track changes over time also addresses a key clinical need, as aneurysm growth patterns inform decisions about intervention versus continued monitoring.

Clinical Limitations and Commercial Plans

Bracco emphasized that the algorithm is not designed to replace comprehensive patient evaluation or a qualified radiologist's image interpretation. The software functions as a decision-support tool rather than an autonomous diagnostic system.

The two companies originally established their partnership in March 2026, focusing on enhancing contrast-based CT imaging. They are now preparing for the commercial launch of Uptunity in the United States, with Avicenna.AI leading promotion and distribution efforts.

The clearance was first reported by Radiology Business.

  • #fda clearance
  • #medical imaging ai
  • #brain aneurysm detection
  • #radiology
  • #ct angiography
  • #bracco

This is an original analysis by the Omega editorial team. Source reporting: AI Watch.

Want systems like this working for your business?

Book a Call

More in AI